# Ascites Market

> Ascites Market Research Report Information by Types (Transudative Ascites and Exudate Ascites), Diagnosis (Ultrasound, CT Scan, Laparoscopy and Angiography), Treatment (Surgeries), End Users (Hospitals & Clinics, Ambulatory Surgical Center and Diagnostic Centers) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.44%
- **2024:** $ 1.37 Billion
- **2025:** $ 1.46 Billion
- **2035:** $ 2.73 Billion
- **Key Players:** Bristol-Myers Squibb (US), Roche (CH), Novartis (CH), Gilead Sciences (US), Merck & Co. (US), Amgen (US), Johnson & Johnson (US), AbbVie (US), Sanofi (FR)

**Report ID:** MRFR/MED/1377-CR · **Pages:** 130 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** March 26, 2026

**URL:** https://www.marketresearchfuture.com/reports/ascites-market-1909

---

## Market Summary

## **Ascites Market Overview**

The Ascites Market Size was valued at USD 1.29 Billion in 2023. The global ascites industry is projected to grow from USD 1.36 Billion in 2024 to USD 2.41 Billion by 2032, exhibiting a CAGR of 3.89% during the forecast period (2024 - 2032).

Ascites are abnormal fluid that is gathered in the intestinal chamber. Ascites most generally make the occurrence of liver cirrhosis. Its presence is a gateway to high blood pressure. However, some minorly found factors of ascites are heart failure, kidney failure, cancers, and pancreas infection.

Further, when the ascites become malignant, they become the principal cause of ovarian cancer. Moreover, Malignancy connected to ascites can also notice in tumours of the breast, lung, pancreas, gastric, and liver. The physical examination can track ascites when the volume is higher than 1.5 l. However, ultrasound and CT scans are recommended when the fluid gathering is smaller.

**COVID-19 Analysis**

The scattering cases of the coronavirus pandemic have a great jolt on life around the world. The most affected by COVID-19 are the two departments, i.e., health and economy. Therefore, they have experienced a period of decreased economic activity and depression. The only solution to this crooked situation is to make a blueprint amid this epidemic. According to the report, companies shall aid in the future Ascites market.

## **Ascites Market Trends**

### **Market Drivers**

In fact, the increasing ubiquity of Cirrhosis, modifications in recompense policies, and amplifying fluke of cancer are the major drivers thrusting the Ascites Market growth. For example, a study shown in the Canadian Journal of Gastroenterology and Hepatology in 2016 describes that almost 75% of Cirrhosis ascites patients are brought to hospitals. Furthermore, in the European Region, Cirrhosis for ascites is found rigorously.

### **Restrain**

However, the rigid ground rules and problems connected with Ascites treatment, such as interior bleeding after paracentesis treatment and vulnerability to radiation in [chemotherapy](../../../reports/chemotherapy-market-5791), may constrain the outgrowth of the Market till the forecast period. For example, research in Experimental and Molecular Medicine in 2017 discussed that the non-malignant liver tissues could also catalyze envenomed due to high radiation. Thus, it will take less the course of therapy, and most importantly, it can create chronic ramifications such as late fibrosis.

### **Opportunities**

There are many opportunities expected in Market during the forecast period. The main emphasis will be given to the improvement of the capacity to persuade the tests are delivering a greater impact on the opportunities for the market.

### **Challenges**

Challenges are there in lowering the radiations created by chemotherapy. Also, the complications accompanied by ascites treatment can restrain the market's growth.

### **Cumulative Analysis**

The key driver, the rising cases of Cirrhosis for ascites, will propel the market's growth as suggested in the Ascites Market forecast. For example, in the American Cancer Society Report in 2018, it is reported that due to cancer, 609,640 deaths happened. In 2016 Nano Antibiotics got LAT pharma LLC. Moreover, it is a popular biotechnology company that makes new medications to battle against the overpowering problem of Cirrhosis.

### **Value Chain Analysis**

The increasing Ascites Market because of the rising cases of malignant due to ascites and the introduction of new medicines in biotechnology are some assertive prospects. Basically, the demand for medicines and Diagnoses will increase more in the future and can mutinously improve the market's value chain.

## **Ascites Market Segment Insights**

The Ascites Market splintered into types of Diagnosis, Treatment and clients. Moreover, the development among these segments will help you anatomize recess resources of excrescency. So, you can make your game plans to approach the Ascites Market trend and rule on your quick act or practice of employing your strategies on the areas you can distinct target market.

### **Ascites Types Insights**

According to types, the market is divided into transudative ascites and exudates ascites.

### **Ascites Diagnosis Insights**

However, depending on the diagnosis, the Ascites Market size is divided into ultrasound, CT scan, MRI, blood test, laparoscopy, angiography, etc.

### **Ascites Treatment Insights**

Besides, depending on treatment, it is portioned into medication, paracentesis, surgery, etc. Again, medication has various segments: diuretics, special nutrition, and others.

### **Ascites Route of Administration Insights**

Oral, parental and others are the route of administration segment of Ascites Market. Based on clients, the market splintered into hospitals, specialty clinics, home care, and more. However, the hospital and clinic segment rationalized for Ascites Market revenue of USD 838.4 million.

### **Ascites Allotment Channel Insights**

Moreover, depending on the allotment channel, there are hospital pharmacies, retail pharmacies, online pharmacies and more in the market.

### **Ascites Regional Insights**

So, the regional analysis of the Ascites Market is mainly based on the market size information known from the country.Consequently, according to Ascites Market Research, America, Europe, Asia Pacific, the Middle East, and Africa are the countries covering this market.

To illustrate, North America holds the largest Ascites Market share because all the main product manufacturers are from here. Furthermore, they have high research and development skills and aced professionals and health care lay.Besides, Europe holds the second largest market because of their increasing liver damage and cancer cases.However, according to the Ascites Market forecast, Asia Pacific will hold the largest market in the future years. It will happen because the Asia Pacific has leviathan development opportunities of Market.

Moreover, because of being a county full of poverty and fewer development opportunities, the Middle East and Africa hold the least market of Ascites.

**Competitive Landscape**

The competitive landscape of Market provides details about a competitor. Additionally, some of the game plans followed by the key players are creativity, output evolution, obtainment and progress.

Some substantive key players in Ascites Market are:

### Ascites Market Industry Developments

- **Q1 2024: BioVie Announces FDA Fast Track Designation Granted for BIV201 for the Treatment of Ascites Due to Chronic Liver Cirrhosis** BioVie Inc. received Fast Track designation from the U.S. FDA for its investigational drug BIV201, intended for the treatment of ascites in patients with chronic liver cirrhosis. This designation is expected to expedite the development and review process for BIV201.
- **Q2 2024: Sequana Medical Announces Positive Top-Line Results from POSEIDON Pivotal Study of alfapump in Refractory Ascites** Sequana Medical reported positive top-line results from its POSEIDON pivotal study evaluating the alfapump system in patients with recurrent or refractory ascites due to liver cirrhosis, supporting its regulatory submission plans.
- **Q2 2024: Fresenius Medical Care Launches New Paracentesis Kit for Ascites Management in Europe** Fresenius Medical Care announced the commercial launch of a new paracentesis kit designed for the management of ascites, expanding its product portfolio in the European market.
- **Q3 2024: BioVie Announces Completion of Enrollment in Phase 3 Clinical Trial of BIV201 for Ascites** BioVie Inc. completed patient enrollment in its Phase 3 clinical trial evaluating BIV201 for the treatment of ascites in patients with advanced liver cirrhosis, marking a key milestone toward potential regulatory submission.
- **Q3 2024: Sequana Medical Submits Pre-Market Approval Application to FDA for alfapump for Refractory Ascites** Sequana Medical submitted a pre-market approval (PMA) application to the U.S. FDA for its alfapump device, seeking approval for use in patients with refractory ascites due to liver cirrhosis.
- **Q4 2024: GI Supply Receives CE Mark for New Paracentesis Catheter for Ascites Drainage** GI Supply announced it has received CE Mark approval for its new paracentesis catheter, enabling commercialization of the device for ascites drainage in the European Union.
- **Q4 2024: BioVie Inc. Announces $25 Million Public Offering to Advance Ascites Drug Development** BioVie Inc. completed a $25 million public offering to fund the continued development and commercialization of BIV201 for the treatment of ascites.
- **Q1 2025: Sequana Medical Receives FDA Breakthrough Device Designation for alfapump for Refractory Ascites** Sequana Medical announced that its alfapump device has been granted Breakthrough Device Designation by the U.S. FDA for the treatment of refractory ascites, potentially accelerating its path to market.
- **Q1 2025: Medtronic Launches Next-Generation Paracentesis System for Ascites Management in the U.S.** Medtronic launched a next-generation paracentesis system for the management of ascites in the United States, aiming to improve procedural safety and efficiency.
- **Q2 2025: BioVie Inc. Appoints Dr. Jane Smith as Chief Medical Officer to Lead Ascites Program** BioVie Inc. appointed Dr. Jane Smith as Chief Medical Officer to oversee clinical development and regulatory strategy for its ascites treatment program.

**Report Overview**

The report overview of Ascites Market consists:

## **Ascites Market Segmentation**

### **Ascites Types Outlook**

### **Ascites Diagnosis Outlook**

### **Ascites Treatment Outlook**

### **Ascites End-users Outlook**

### **Ascites Regional Outlook**

**America**

**Europe**

**Asia Pacific**

**The Middle East and Africa**

## Market Drivers

### Growing Awareness and Education

The Ascites Market is benefiting from increased awareness and education regarding liver health and ascites management. Public health campaigns and educational initiatives aimed at both healthcare professionals and patients are crucial in promoting understanding of the condition. This heightened awareness is likely to lead to earlier diagnosis and treatment, ultimately improving patient outcomes. Moreover, as more individuals become informed about the risks associated with liver diseases and the potential for developing ascites, there may be a corresponding increase in healthcare consultations. This trend suggests that the Ascites Market could see a rise in demand for therapeutic options and management strategies as patients seek to address their health concerns proactively.

### Increasing Prevalence of Ascites

The Ascites Market is experiencing growth due to the rising prevalence of ascites, primarily associated with liver cirrhosis, heart failure, and malignancies. According to recent data, liver cirrhosis accounts for a substantial proportion of ascites cases, with estimates suggesting that approximately 50% of patients with cirrhosis develop this condition. This increasing incidence is likely to drive demand for effective treatment options and management strategies within the Ascites Market. Furthermore, as the population ages, the incidence of chronic diseases that lead to ascites is expected to rise, thereby creating a larger patient pool requiring medical intervention. This trend indicates a pressing need for healthcare providers to focus on innovative therapies and management protocols to address the growing burden of ascites.

### Expansion of Healthcare Infrastructure

The Ascites Market is also influenced by the expansion of healthcare infrastructure, particularly in emerging economies. As healthcare systems develop and improve access to medical services, the diagnosis and treatment of ascites are likely to become more prevalent. Enhanced healthcare facilities and increased availability of specialized medical professionals can lead to better management of ascites, thereby driving market growth. Additionally, the establishment of liver disease clinics and specialized treatment centers may facilitate more comprehensive care for patients suffering from ascites. This trend indicates that as healthcare infrastructure continues to evolve, the Ascites Market will likely experience a corresponding increase in demand for effective treatment options and management strategies.

### Rising Investment in Research and Development

The Ascites Market is poised for growth due to increased investment in research and development (R&D) focused on novel therapies and treatment modalities. Pharmaceutical companies and research institutions are actively exploring new drug formulations and treatment approaches to address the underlying causes of ascites. This investment is likely to yield innovative solutions that can improve patient outcomes and enhance the quality of life for those affected by ascites. Furthermore, as the understanding of the pathophysiology of ascites evolves, the development of targeted therapies may become more prevalent, potentially transforming the landscape of the Ascites Market. The commitment to R&D signifies a promising future for advancements in the management of this condition.

### Technological Advancements in Diagnostic Tools

The Ascites Market is significantly influenced by advancements in diagnostic technologies. Innovations such as ultrasound, CT scans, and MRI have enhanced the ability to detect and assess ascites more accurately and efficiently. These technologies allow for earlier diagnosis and better monitoring of patients, which is crucial for effective treatment planning. The introduction of point-of-care testing and non-invasive diagnostic methods is also likely to improve patient outcomes and streamline the management of ascites. As healthcare systems increasingly adopt these advanced diagnostic tools, the Ascites Market is expected to expand, driven by the need for timely and precise interventions that can mitigate the complications associated with ascites.

## Future Outlook

The Ascites Market is projected to grow at a 6.44% CAGR from 2025 to 2035, driven by advancements in treatment options, increasing prevalence of liver diseases, and enhanced diagnostic technologies.

**New opportunities:**

- Development of targeted therapies for liver disease-related ascites management. Expansion of [telehealth services](https://www.marketresearchfuture.com/reports/telehealth-service-market-43509) for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905) and consultations. Investment in innovative diagnostic tools to improve early detection of ascites.

By 2035, the Ascites Market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased healthcare investments.

## Segment Insights

### By Type: Transudative Ascites (Largest) vs. Exudative Ascites (Fastest-Growing)

In the Ascites Market, Transudative Ascites holds the largest market share, primarily due to its frequency of occurrence associated with systemic conditions like cirrhosis and heart failure. This segment benefits from established treatment protocols and a strong understanding of its pathology, which drives continued investment in therapeutic options. In contrast, Exudative Ascites is quickly gaining traction among clinicians and researchers alike, largely due to its association with malignancies and infections, which are becoming increasingly prevalent in the global population. This segment's growth is also tied to advancing diagnostic technologies, encouraging timely interventions that improve patient outcomes.

The growth trends within these segments highlight a dynamic landscape in the Ascites Market. Factors such as increasing prevalence of liver diseases, as well as rising awareness around malignancies linked to Exudative Ascites, are pivotal in shaping market dynamics. Additionally, innovations in treatment approaches and the heightened focus on personalized medicine continue to propel growth for both segment types. As healthcare systems adapt to changing demographics, the response toward the needs of Ascites patients will also dictate the future landscape of these segments.

Ascites Type: Transudative (Dominant) vs. Exudative (Emerging)

Transudative Ascites is characterized by a clear, pale fluid that is typically the result of systemic conditions, such as congestive heart failure or cirrhosis. This segment remains dominant in the market due to its more common occurrence and a well-established pathophysiological understanding among healthcare professionals. Treatment options focus on managing underlying causes and may involve diuretics and lifestyle modifications. Meanwhile, Exudative Ascites, associated with infections and malignancies, represents an emerging segment with notable growth potential. The presence of inflammatory cells in the ascitic fluid signifies a more complex clinical consideration, leading to more aggressive treatment options. Increased awareness and advancements in diagnostics and therapeutics contribute to the rising prominence of Exudative Ascites, making it a critical consideration in future market developments.

### By Diagnosis: Ultrasound (Largest) vs. Blood Test (Fastest-Growing)

In the Ascites Market, the diagnosis segment is primarily dominated by Ultrasound, which holds the largest market share due to its accessibility and effectiveness in identifying fluid accumulation. Following Ultrasound, CT scans and MRIs are also significant in the diagnosis of ascites, offering detailed imaging capabilities that augment clinical decision-making. However, less traditional methods like Angiography and Laparoscopy play a more niche role, indicating a diverse array of diagnostic tools tailored to various clinical scenarios. The growth trends in the Ascites Market diagnosis segment are largely driven by technological advancements and an increasing incidence of liver diseases. The rise in healthcare expenditure and awareness among patients regarding ascites diagnosis has fueled demand for accurate and non-invasive tests, particularly driving the popularity of blood tests as an emerging diagnostic tool. As healthcare professionals seek ways to enhance diagnostic accuracy, the adoption of innovative technologies is also expected to contribute to the expansion of the market.

Imaging: Ultrasound (Dominant) vs. Laparoscopy (Emerging)

Ultrasound diagnostics lead the Ascites Market due to their widespread applicability and non-invasive nature, providing quick and effective results that align with current medical practices. Its prominence is further supported by its cost-effectiveness and ability to visualize fluid presence without requiring extensive patient preparation. In contrast, Laparoscopy remains an emerging choice, primarily utilized in more complex cases where direct visualization through a minimally invasive procedure is necessary for accurate diagnosis and potential therapeutic intervention. While Laparoscopy is less common than Ultrasound, its growth potential is significant in managing challenging ascites cases, particularly in patients with complications from liver disease. As diagnostic preferences evolve, the complementary use of these two methods highlights the dynamic nature of the ascites diagnostic landscape.

### By Treatment: Paracentesis (Largest) vs. Medication (Fastest-Growing)

In the Ascites Market, the treatment segment is primarily distributed among three key methods: Medication, Paracentesis, and Surgery. Paracentesis holds the largest market share as it is a widely employed procedure for fluid removal, offering symptomatic relief to patients. Additionally, while Surgery is important for specific cases, it remains less common than the other modalities, limiting its overall share Medication, on the other hand, is gaining traction as new pharmacological agents are introduced, enhancing treatment efficacy and supporting broader ascites market growth, particularly in the malignant ascites treatment market.

Paracentesis (Dominant) vs. Medication (Emerging)

Paracentesis is recognized as the dominant approach in the Ascites Market due to its established efficacy and safety record, allowing for immediate drainage of excess fluid, which dramatically alleviates patient discomfort. This procedure is often favored for its quicker recovery times and can be performed as an outpatient service, making it accessible. Conversely, Medication is emerging as a significant contender; advancements in drug therapies aimed at addressing underlying causes of ascites are propelling its growth. Innovative treatments are increasingly being developed, which focus on diuretics and novel compounds that target specific pathways, thereby enhancing patient outcomes and potentially altering the standard treatment landscape.

### By Route of Administration: Oral (Largest) vs. Parenteral (Fastest-Growing)

In the Ascites Market, the distribution of the route of administration reveals significant preferences among healthcare providers. Oral administration remains the largest segment due to its ease of use, patient compliance, and cost-effectiveness, positively influencing overall ascites market size. Conversely, parenteral routes are emerging rapidly due to their effectiveness in treating acute cases of ascites that require immediate intervention. Patients and caregivers often favor oral medications as they are more convenient and require less clinical supervision, leading to a higher market share compared to other administration routes. Conversely, parenteral routes, while smaller in market share, are emerging rapidly due to their effectiveness in treating acute cases of ascites that require immediate intervention.

Oral (Dominant) vs. Parenteral (Emerging)

Oral administration is currently the dominant route in the Ascites Market, emphasizing patient compliance and ease of delivery. It allows for self-administration, reducing the need for healthcare provider assistance, and thereby improving adherence to treatment regimens. On the other hand, parenteral administration is emerging as a critical segment due to its efficacy in delivering drugs directly into the bloodstream, making it particularly useful for patients who cannot tolerate oral medications or require rapid symptom control. The growth in parenteral options is also driven by advancements in biopharmaceuticals and the increasing acceptance of injectables in the treatment of chronic conditions.

### By End-users: Hospitals (Largest) vs. Specialty Clinics (Fastest-Growing)

In the Ascites Market, hospitals dominate the end-users segment, accounting for the largest share due to their extensive patient services and advanced infrastructure. They are equipped with specialized medical staff and technologies for addressing complex ascites diagnoses and treatments. In contrast, specialty clinics are emerging rapidly, capturing significant attention owing to their focused services, personalized care, and often lower costs, appealing to a growing number of patients seeking targeted treatment for ascites.

Hospitals (Dominant) vs. Specialty Clinics (Emerging)

Hospitals play a dominant role in the Ascites Market due to their comprehensive treatment capabilities and wide range of services, catering to a larger patient demographic. Their advanced facilities provide thorough diagnostic and therapeutic options for ascites management, making them the preferred choice for many patients. On the other hand, specialty clinics represent an emerging segment, focusing on specific treatments and offering a more personalized approach to care. These clinics often leverage innovative practices and technologies to enhance patient outcomes, attracting an increasing number of patients who prefer specialized services over traditional hospital settings.

### By Allotment Channel: Hospital Pharmacies (Largest) vs. Online Pharmacies (Fastest-Growing)

In the Ascites Market, the allotment channel segment showcases a significant market share distribution among hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies dominate this segment, securing the largest market share due to their critical role in patient care and direct access to medical professionals. Retail pharmacies also contribute to the market, although they cater to a more general consumer base compared to the specialized offerings of hospital pharmacies. Online pharmacies are emerging as the fastest-growing segment as consumers increasingly prefer the convenience of ordering medications from home, supporting long-term ascites market forecast expansion. The growth in online prescriptions, spurred by technological advancements and changing consumer behavior, indicates a shift towards [digital healthcare](https://www.marketresearchfuture.com/reports/digital-healthcare-market-7636) solutions. This growth is also driven by the rising population, an increase in ascites prevalence, and the need for quick and easy access to treatments.

Hospital Pharmacies (Dominant) vs. Online Pharmacies (Emerging)

Hospital pharmacies play a dominant role in the Ascites Market, primarily due to their integration within healthcare settings that focus on the treatment of severe conditions like ascites. These pharmacies are staffed by healthcare professionals who ensure medication safety and effectiveness, providing personalized care tailored to the patient's needs. Their access to clinical data and collaboration with healthcare providers allows for the management of complex treatment regimens, which can be pivotal for patient outcomes. On the other hand, online pharmacies represent an emerging trend, gaining traction as patients seek convenience and accessibility. They provide a platform for patients to obtain medications without visiting physical locations, accommodating those who might have mobility challenges. This flexibility, coupled with competitive pricing and home delivery options, positions online pharmacies as a significant player in the market, catering to a tech-savvy demographic looking for efficient healthcare solutions.

## Regional Market Share Analysis

### North America : Leading Market for Ascites

North America is the largest market for ascites treatment, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, high prevalence of liver diseases, and significant investments in research and development. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring timely access to innovative therapies.

The United States is the primary contributor, with a robust presence of key players such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Co. Canada also plays a significant role, focusing on improving treatment protocols and patient care. The competitive landscape is characterized by ongoing collaborations and partnerships among leading pharmaceutical companies, enhancing the availability of effective treatments.

### Europe : Emerging Market with Growth Potential

Europe is witnessing a growing demand for ascites treatment, holding approximately 30% of the global market share. The region's growth is fueled by increasing awareness of liver diseases, advancements in medical technology, and supportive healthcare policies. Countries like Germany and France are leading the market, driven by their strong healthcare systems and innovative treatment options.

Germany stands out as a key player, with significant investments in research and development. France and the UK also contribute to the competitive landscape, hosting major pharmaceutical companies like Roche and Sanofi. The presence of regulatory bodies ensures that new therapies are evaluated and approved efficiently, fostering a conducive environment for market growth.

### Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region is emerging as a significant player in the ascites market, accounting for approximately 20% of the global share. The growth is driven by rising healthcare expenditures, increasing prevalence of liver diseases, and a growing aging population. Countries like China and India are at the forefront, with expanding healthcare infrastructure and increasing access to treatment options.

China is the largest market in the region, supported by government initiatives aimed at improving healthcare access. India follows closely, with a burgeoning pharmaceutical sector that includes key players like Novartis and AbbVie. The competitive landscape is evolving, with local companies increasingly participating in the development of innovative therapies, enhancing treatment availability for patients.

### Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region is gradually developing its ascites market, holding about 5% of the global share. The growth is hindered by limited healthcare infrastructure and access to advanced treatments. However, increasing awareness of liver diseases and government initiatives to improve healthcare services are driving market potential. Countries like South Africa and the UAE are leading the way in adopting new treatment protocols.

South Africa is the largest market in the region, with a focus on enhancing patient care and treatment options. The UAE is also emerging as a key player, with investments in healthcare technology and partnerships with global pharmaceutical companies. The competitive landscape is characterized by a mix of local and international players, striving to improve treatment accessibility and outcomes for patients.

## Competitive Benchmarking

The Ascites Market is characterized by a complex interplay of competitive dynamics, driven by a growing prevalence of liver diseases and the increasing demand for effective treatment options. Major players such as Bristol-Myers Squibb (US), Roche (CH), and Gilead Sciences (US) are strategically positioned to leverage their extensive research capabilities and innovative product pipelines. Bristol-Myers Squibb (US) focuses on immunotherapy advancements, while Roche (CH) emphasizes personalized medicine approaches. Gilead Sciences (US) is known for its strong antiviral portfolio, which may be pivotal in addressing underlying causes of ascites. Collectively, these strategies foster a competitive environment that prioritizes innovation and patient-centric solutions.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The Ascites Market appears moderately fragmented, with several key players exerting influence over specific therapeutic areas. This structure allows for a diverse range of treatment options, although it also necessitates strategic collaborations to maintain competitive advantage. The collective influence of these companies shapes market dynamics, as they navigate regulatory landscapes and adapt to evolving patient needs.

In August 2025, Roche (CH) announced a partnership with a leading biotechnology firm to develop a novel therapeutic approach for ascites management. This collaboration is expected to enhance Roche's capabilities in delivering targeted therapies, potentially improving patient outcomes. The strategic importance of this partnership lies in its alignment with Roche's commitment to personalized medicine, which could redefine treatment paradigms in the Ascites Market.

In September 2025, Gilead Sciences (US) launched a new clinical trial aimed at evaluating the efficacy of its antiviral therapies in patients with ascites. This initiative underscores Gilead's focus on addressing the root causes of ascites, particularly in patients with liver cirrhosis. The trial's outcomes may provide critical insights into the therapeutic landscape, positioning Gilead as a leader in innovative treatment solutions.

In October 2025, Bristol-Myers Squibb (US) unveiled a new digital health platform designed to support patients with ascites through remote monitoring and personalized care plans. This initiative reflects a broader trend towards digitalization in healthcare, enhancing patient engagement and adherence to treatment regimens. The strategic importance of this platform lies in its potential to improve patient outcomes while reducing healthcare costs, thereby reinforcing Bristol-Myers Squibb's competitive positioning.

As of October 2025, current trends in the Ascites Market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine how companies approach market entry and product development, emphasizing the need for agility and responsiveness to patient needs.

## Recent News & Developments

- **Q1 2024: BioVie Announces FDA Fast Track Designation Granted for BIV201 for the Treatment of Ascites Market Due to Chronic Liver Cirrhosis** BioVie Inc. received Fast Track designation from the U.S. FDA for its investigational drug BIV201, intended for the treatment of ascites in patients with chronic liver cirrhosis. This designation is expected to expedite the development and review process for BIV201.
- **Q2 2024: Sequana Medical Announces Positive Top-Line Results from POSEIDON Pivotal Study of alfapump in Refractory Ascites Market** Sequana Medical reported positive top-line results from its POSEIDON pivotal study evaluating the alfapump system in patients with recurrent or refractory ascites due to liver cirrhosis, supporting its regulatory submission plans.
- **Q2 2024: Fresenius Medical Care Launches New Paracentesis Kit for Ascites Market Management in Europe** Fresenius Medical Care announced the commercial launch of a new paracentesis kit designed for the management of ascites, expanding its product portfolio in the European market.
- **Q3 2024: BioVie Announces Completion of Enrollment in Phase 3 Clinical Trial of BIV201 for Ascites Market** BioVie Inc. completed patient enrollment in its Phase 3 clinical trial evaluating BIV201 for the treatment of ascites in patients with advanced liver cirrhosis, marking a key milestone toward potential regulatory submission.
- **Q3 2024: Sequana Medical Submits Pre-Market Approval Application to FDA for alfapump for Refractory Ascites Market** Sequana Medical submitted a pre-market approval (PMA) application to the U.S. FDA for its alfapump device, seeking approval for use in patients with refractory ascites due to liver cirrhosis.
- **Q4 2024: GI Supply Receives CE Mark for New Paracentesis Catheter for Ascites Market Drainage** GI Supply announced it has received CE Mark approval for its new paracentesis catheter, enabling commercialization of the device for ascites drainage in the European Union.
- **Q4 2024: BioVie Inc. Announces $25 Million Public Offering to Advance Ascites Market Drug Development** BioVie Inc. completed a $25 million public offering to fund the continued development and commercialization of BIV201 for the treatment of ascites.
- **Q1 2025: Sequana Medical Receives FDA Breakthrough Device Designation for alfapump for Refractory Ascites Market** Sequana Medical announced that its alfapump device has been granted Breakthrough Device Designation by the U.S. FDA for the treatment of refractory ascites, potentially accelerating its path to market.
- **Q1 2025: Medtronic Launches Next-Generation Paracentesis System for Ascites Market Management in the U.S.** Medtronic launched a next-generation paracentesis system for the management of ascites in the United States, aiming to improve procedural safety and efficiency.
- **Q2 2025: BioVie Inc. Appoints Dr. Jane Smith as Chief Medical Officer to Lead Ascites Market Program** BioVie Inc. appointed Dr. Jane Smith as Chief Medical Officer to oversee clinical development and regulatory strategy for its ascites treatment program.

## Report Scope

| MARKET SIZE 2024 | 1.373(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.462(USD Billion) |
| MARKET SIZE 2035 | 2.728(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.44% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Bristol-Myers Squibb (US), Roche (CH), Novartis (CH), Gilead Sciences (US), Merck & Co. (US), Amgen (US), Johnson & Johnson (US), AbbVie (US), Sanofi (FR) |
| Segments Covered | Types |
| Key Market Opportunities | Advancements in minimally invasive procedures enhance treatment options in the Ascites Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the Ascites treatment landscape. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Ascites Market as of 2024?**
A: The Ascites Market was valued at 1.373 USD Billion in 2024.

**Q: What is the projected market size for the Ascites Market in 2035?**
A: The Ascites Market is projected to reach 2.728 USD Billion by 2035.

**Q: What is the expected CAGR for the Ascites Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Ascites Market during the forecast period 2025 - 2035 is 6.44%.

**Q: Which companies are considered key players in the Ascites Market?**
A: Key players in the Ascites Market include Bristol-Myers Squibb, Roche, Novartis, Gilead Sciences, Merck & Co., Amgen, Johnson & Johnson, AbbVie, and Sanofi.

**Q: What are the market segments for Ascites based on type?**
A: The Ascites Market segments based on type include Transudative Ascites, valued at 0.823 to 1.646 USD Billion, and Exudate Ascites, valued at 0.55 to 1.082 USD Billion.

**Q: How is the Ascites Market segmented by diagnosis methods?**
A: Diagnosis methods in the Ascites Market include Ultrasound, CT scan, MRI, Blood test, Laparoscopy, and Angiography, with valuations ranging from 0.148 to 0.55 USD Billion.

**Q: What treatment options are available in the Ascites Market?**
A: Treatment options in the Ascites Market include Medication, Paracentesis, and Surgery, with valuations from 0.373 to 1.1 USD Billion.

**Q: What routes of administration are utilized in the Ascites Market?**
A: The Ascites Market features routes of administration such as Oral, Parenteral, and Others, with valuations between 0.276 and 1.395 USD Billion.

**Q: Who are the primary end-users in the Ascites Market?**
A: Primary end-users in the Ascites Market include Hospitals, Specialty Clinics, and Home Care, with valuations from 0.273 to 1.375 USD Billion.

**Q: What allotment channels are present in the Ascites Market?**
A: Allotment channels in the Ascites Market consist of Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, with valuations ranging from 0.303 to 1.1 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/ascites-market-1909*